Havas rises on Q2 growth and attractive healthcare exposure

Havas NV

30/07/2025 08:54

** French advertising company Havas HAVAS.AS climbs around 3% after reporting Q2 organic growth of 2.6%, beating expectations and reaffirming FY guidance

** J.P. Morgan highlights in a note Havas’s attractive valuation and strong balance sheet as key factors supporting its stock performance

** Higher exposure than peers to Healthcare should be a medium-term positive despite US regulatory uncertainty, broker says

** "We upgrade our FY25 organic growth slightly from 2.1% to 2.5% given a strong H1 & what should be easier H2 comps" - JPM adds

** JPM keeps "overweight" rating and PT of 2.0 euros with a 10% governance discount

** "Interests of minorities may not always align with those of Bollore, which owns 31% and has effective control," analysts add

 (Reporting by Leo Marchandon)

 ((Leo.marchandon@thomsonreuters.com))